Abstract
Rationale
Paired associates learning (PAL) has been suggested to be predictive of functional outcomes in first episode psychosis and of conversion from mild cognitive impairment to Alzheimer’s disease. An automated touch screen-based rodent PAL (rPAL) task has been developed and is sensitive to manipulations of the dopaminergic and glutamatergic system. Accordingly, rPAL when used with pharmacological models of schizophrenia, like NMDA receptor blockade with MK-801 or dopaminergic stimulation with amphetamine, may have utility as a translational model of cognitive impairment in schizophrenia.
Objective
The purpose of this study was to determine if amphetamine- and MK-801-induced impairment represent distinct models of cognitive impairment by testing their sensitivity to common antipsychotics and determine the relative contributions of D1 versus D2 receptors on performance of PAL.
Method
Rats were trained in rPAL and were then treated with MK-801, amphetamine, risperidone, haloperidol, quinpirole, SK-82958, or SCH-23390 alone and in combination.
Results
While both amphetamine and MK-801 caused clear impairments in accuracy, MK-801 induced a profound “perseverative” type behavior that was more pronounced when compared to amphetamine. Moreover, amphetamine-induced impairments, but not the effects of MK-801, could be reversed by antipsychotics as well as the D1 receptor antagonist SCH-23390, suggesting a role for both the D1 and D2 receptor in the amphetamine impairment model.
Conclusions
These data suggest that amphetamine and MK-801 represent dissociable models of impairment in PAL, dependent on different underlying neurobiology. The ability to distinguish dopaminergic versus glutamatergic effects on performance in rPAL makes it a unique and useful tool in the modeling of cognitive impairments in schizophrenia.
Similar content being viewed by others
Notes
The amphetamine impairment model has proven to be very consistent. We have employed this challenge in over 20 studies and have only once observed a lack of an amphetamine effect. In contrast, the MK-801 model has been more difficult to employ. 0.05 mg/kg will cause deficits in percent correct with no effects on secondary measures; however, this dose may lack the consistency needed for repeated drug screening. In contrast at 0.075 mg/kg MK-801 did consistently cause a decrease in percent correct, but this same dose will also cause substantial increases in response latencies. Since response latency is preferentially affected by MK-801 over collection latency, this may represent cognitive slowing as opposed to non-specific behavioral changes. However, we cannot rule out the possibility that some of the effects observed on percent correct after an MK-801 challenge are non-cognitive in nature.
References
Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1–S5
Angrist B, Sathananthan G, Wilk S, Gershon S (1974) Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11:13–23
Ballard TM, Wyler R, Burns T (2013) Comparison of scopolamine and MK801 effects on touchscreen based cognitive tasks in rats. The annual meeting of the Society for Neuroscience
Barnett JH, Sahakian BJ, Werners U, Hill KE, Brazil R, Gallagher O, Bullmore ET, Jones PB (2005) Visuospatial learning and executive function are independently impaired in first-episode psychosis. Psychol Med 7:1031–1041
Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD (2010) Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev 34:1161–1177
Blackwell AD, Sahakian BJ, Vesey R, Sample JM, Robbins TW, Hodges JR (2004) Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease. Dement Geriatr Cogn Disord 17:42–48
Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, Bogerts B, Braun AK, Jankowski Z, Kumaritlake J, Henneberg M, Gos T (2014) The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 5:47
Bussey TJ, Barch DM, Baxter MG (2013) Testing long-term memory in animal models of schizophrenia: suggestions from CNTRICS. Neurosci Biobehav Rev 37:2141–2148
Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–186
Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, Tricklebank M (2012) NMDA receptors, cognition and schizophrenia—testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62:1401–1412
Hagan JJ, Jones DN (2005) Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull 31:830–853
Herron CE, Lester RA, Coan EJ, Collingridge GL (1986) Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism. Nature 322:265–268
Hunt MJ, Kasicki S (2013) A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo. J Psychopharmacol 27:972–986
Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215–233
Lau CI, Wang HC, Hsu JL, Liu ME (2013) Does the dopamine hypothesis explain schizophrenia? Rev Neurosci 24:389–400
Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T (2009) Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34:74–89
Nithianantharajah J, Komiyama NH, McKechanie A, Johnstone M, Blackwood DH, St CD, Emes RD, van de Lagemaat LN, Saksida LM, Bussey TJ, Grant SG (2013) Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nat Neurosci 16:16–24
Roberts AC, Reekie Y, Braesicke K (2007) Synergistic and regulatory effects of orbitofrontal cortex on amygdala-dependent appetitive behavior. Ann N Y Acad Sci 1121:297–319
Robertson SD, Matthies HJ, Galli A (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39:73–80
Sulzer D, Sonders MS, Galli A (2005) Mechanisms of neurotransmitter release my amphetamines: a review. Prog Neurobiol 75:406–433
Talpos J, Steckler T (2013) Touching on translation. Cell Tissue Res 354:297–308
Talpos JC, Winters BD, Dias R, Saksida LM, Bussey TJ (2009) A novel touchscreen-automated paired-associate learning (PAL) task sensitive to pharmacological manipulation of the hippocampus: a translational rodent model of cognitive impairments in neurodegenerative disease. Psychopharmacology (Berl) 205:157–168
Talpos JC, Fletcher AC, Circelli C, Tricklebank MD, Dix SL (2012) The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli. Psychopharmacology (Berl) 221:437–449
Talpos JC, Aerts N, Fellini L, Steckler T (2014) A touch-screen based paired-associates learning (PAL) task for the rat may provide a translatable pharmacological model of human cognitive impairment. Pharmacol Biochem Behav 122:97–106
Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21–36
Acknowledgments
NEWMEDS—the research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under Grant agreement no. 115008 of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Talpos, J., Aerts, N., Waddell, J. et al. MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia. Psychopharmacology 232, 3911–3920 (2015). https://doi.org/10.1007/s00213-015-3934-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-015-3934-x